HP expands collaboration with Tecan, launching a new digital dispenser for single-cell and low volume applications

Männedorf, Switzerland, May 20, 2025 – Tecan Group (SIX Swiss Exchange: TECN) announced today that it has expanded its collaboration with HP to launch the Duo Digital Dispenser™ — a powerful new solution that combines single-cell and reagent dispensing in one streamlined system. Designed to simplify complex workflows and support faster, more reproducible results, Duo is powered by HP’s inkjet technology and brings together the proven capabilities of the Uno Single Cell Dispenser™ and D300e Digital Dispenser offered by Tecan.

By combining single-cell and reagent dispensing into one system, the new instrument significantly improves lab efficiency, reducing sample processing time, increasing reproducibility, and cutting down on labware waste and reagent use. Duo is 40 times faster than conventional methods[1]  for drug discovery, reducing dosing time from 10 minutes to 15 seconds. Cell dispensing with Duo enables researchers to isolate single cells in less than 5 minutes compared to 1 hour when using traditional cell isolation technology[2]. The instrument features a single-use disposable component that simplifies setup, minimizes contamination risk, and enables experimental reproducibility.

In addition to dispensing cells, Duo enables researchers to dispense reagents without the use of surfactants. This innovation is especially important for scientists developing advanced biologic therapeutics, which can be particularly sensitive to surfactants.

“With the Duo Digital Dispenser, we’re delivering on the promise of HP’s inkjet and microfluidics technology to transform how life science research is done,” said Bao Nguyen, Vice President and General Manager of Specialty Printing & Technology Solutions at HP. “By simplifying complex lab workflows and increasing accessibility, we’re helping researchers spend more time on discovery and less on setup. It’s incredibly rewarding to see our technology accelerate progress in personalized medicine through our work with Tecan. We’re proud to be a partner in maximizing the potential of this revolutionary technology.”

As single-cell research and advances in therapeutic development pave the way for personalized medicine, this ongoing collaboration between HP and Tecan makes next-generation inkjet-based microfluidics accessible to a wider range of labs, including those without deep specialization. This broader adoption has the potential to significantly accelerate the development and delivery of life-changing therapeutics.

“Tecan is proud to be an industry leader in lab automation and application solutions for life sciences,” said Mukta Acharya, Executive Vice President of Tecan’s Life Sciences Division. “By combining HP’s innovative microfluidics with Tecan’s deep application expertise and global reach, we’re delivering greater precision, efficiency, and ease of use for single-cell and drug-discovery applications. We’re helping customers to scale healthcare innovation.” 

Tecan and HP will continue working together to build on this platform, combining advanced microfluidics with deep application expertise to further accelerate innovation in single-cell and drug discovery workflows.

[1] Based on HP internal data conducted May 2025 using 8-point triplicate, serial dilution with hand pipette
[2] Based on HP internal data conducted May 2025 using a 96-well plate, FACS single cell isolation

For more information about Duo Digital Dispenser™, please visit
https://www.tecan.com/duo

For further information:
Tecan Group
Martin Brändle
Senior Vice President, Corporate Communications & IR
Tel. +41 (0) 44 922 84 30
investor@tecan.com

About Tecan

Tecan (www.tecan.com) improves people’s lives and health by empowering customers to scale healthcare innovation globally from life science to the clinic. Tecan is a pioneer and global leader in laboratory automation. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments, components and medical devices that are then distributed by partner companies. Founded in Switzerland in 1980, the company has 3,300 employees, with manufacturing, research and development sites in Europe, North America and Asia, and maintains a sales and service network in over 70 countries. In 2023, Tecan generated sales of CHF 934 million (USD 1,062 million; EUR 984 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).